Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, p... von Powles, Thomas, Plimack, Elizabeth R, Soulières, Denis, Waddell, Tom, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Pouliot, Frédéric, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J, Borchiellini, Delphine, McDermott, Raymond S, Bedke, Jens, Tamada, Satoshi, Yin, Lina, Chen, Mei, Molife, L Rhoda, Atkins, Michael B, Rini, Brian I

Volltext

Cancer therapeutics: Targeting the apoptotic pathway von Khan, Khurum H, Blanco-Codesido, Montserrat, Molife, L. Rhoda

Volltext

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma von Bedke, Jens, Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dimitry, Pouliot, Frederic, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J., Borchiellini, Delphine, McDermott, Raymond S., Tamada, Satoshi, Nguyen, Allison Martin, Wan, Shuyan, Perini, Rodolfo F., Rhoda Molife, L., Atkins, Michael B., Powles, Thomas

Volltext

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer von Attard, Gerhardt, Reid, Alison H M, A'Hern, Roger, Parker, Christopher, Oommen, Nikhil Babu, Folkerd, Elizabeth, Messiou, Christina, Molife, L Rhoda, Maier, Gal, Thompson, Emilda, Olmos, David, Sinha, Rajesh, Lee, Gloria, Dowsett, Mitch, Kaye, Stan B, Dearnaley, David, Kheoh, Thian, Molina, Arturo, de Bono, Johann S

Volltext

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Uro... von Plimack, Elizabeth R, Powles, Thomas, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Waddell, Tom, Alekseev, Boris, Pouliot, Frédéric, Melichar, Bohuslav, Soulières, Denis, Borchiellini, Delphine, McDermott, Raymond S, Vynnychenko, Ihor, Chang, Yen-Hwa, Tamada, Satoshi, Atkins, Michael B, Li, Chenxiang, Perini, Rodolfo, Molife, L Rhoda, Bedke, Jens, Rini, Brian I

Volltext

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate von Reid, Alison H M, Attard, Gerhardt, Danila, Daniel C, Oommen, Nikhil Babu, Olmos, David, Fong, Peter C, Molife, L Rhoda, Hunt, Joanne, Messiou, Christina, Parker, Christopher, Dearnaley, David, Swennenhuis, Joost F, Terstappen, Leon W M M, Lee, Gloria, Kheoh, Thian, Molina, Arturo, Ryan, Charles J, Small, Eric, Scher, Howard I, de Bono, Johann S

Volltext

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours von Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca

Volltext

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers von Perkins, Geraldine, Yap, Timothy A, Pope, Lorna, Cassidy, Amy M, Dukes, Juliet P, Riisnaes, Ruth, Massard, Christophe, Cassier, Philippe A, Miranda, Susana, Clark, Jeremy, Denholm, Katie A, Thway, Khin, Gonzalez De Castro, David, Attard, Gerhardt, Molife, L Rhoda, Kaye, Stan B, Banerji, Udai, de Bono, Johann S

Volltext

Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities? von Postel-Vinay, Sophie, Gomez-Roca, Carlos, Molife, L Rhoda, Anghan, Bhavesh, Levy, Antonin, Judson, Ian, De Bono, Johann, Soria, Jean-Charles, Kaye, Stan, Paoletti, Xavier

Volltext

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort stu... von Olmos, David, MD, Postel-Vinay, Sophie, MD, Molife, L Rhoda, MD, Okuno, Scott H, MD, Schuetze, Scott M, MD, Paccagnella, M Luisa, PhD, Batzel, Gretchen N, MD, Yin, Donghua, PhD, Pritchard-Jones, Kathryn, Prof, Judson, Ian, Prof, Worden, Francis P, MD, Gualberto, Antonio, MD, Scurr, Michelle, MD, de Bono, Johann S, Dr, Haluska, Paul, MD

Volltext

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors von HALUSKA, Paul, SHAW, Heather M, ADJEI, Alex A, DE BONO, Johann S, BATZEL, Gretchen N, YIN, Donghua, MOLINA, Julian R, MOLIFE, L. Rhoda, YAP, Timothy A, ROBERTS, M. Luisa, SHARMA, Amarnath, GUALBERTO, Antonio

Volltext

Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours von Kristeleit, Rebecca, Evans, Jeffry, Molife, L. Rhoda, Tunariu, Nina, Shaw, Heather, Slater, Sarah, Haris, Noor R. Md, Brown, Nicholas F., Forster, Martin D., Diamantis, Nikolaos, Rulach, Robert, Greystoke, Alastair, Asghar, Uzma, Rata, Mihaela, Anderson, Stephanie, Bachmann, Felix, Hannah, Alison, Kaindl, Thomas, Lane, Heidi A., Larger, Patrice J., Schmitt-Hoffmann, Anne, Engelhardt, Marc, Tzankov, Alexandar, Plummer, Ruth, Lopez, Juanita

Volltext

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies von Dirix, Luc, MD, PhD, Swaisland, Helen, Verheul, Henk M.W., MD, PhD, Rottey, Sylvie, MD, PhD, Leunen, Karin, MD, Jerusalem, Guy, MD, PhD, Rolfo, Christian, MD, PhD, Nielsen, Dorte, MD, DMSc, Molife, L. Rhoda, BMedSci, BM BS, MRCP, MD, MSc, Kristeleit, Rebecca, BSc, MRCP, PhD, Vos-Geelen, Judith de, MD, PhD, Mau-Sørensen, Morten, MD, PhD, Soetekouw, Patricia, MD, van Herpen, Carla, MD, PhD, Fielding, Anitra, MBChB, So, Karen, MBBS, MRCS, MD, Bannister, Wendy, Plummer, Ruth, MD, D.Phil, FRCP

Volltext

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer von Rafii, Saeed, Gourley, Charlie, Kumar, Rajiv, Geuna, Elena, Ern Ang, Joo, Rye, Tzyvia, Chen, Lee-May, Shapira-Frommer, Ronnie, Friedlander, Michael, Matulonis, Ursula, De Greve, Jacques, Oza, Amit M, Banerjee, Susana, Molife, L Rhoda, Gore, Martin E, Kaye, Stan B, Yap, Timothy A

Volltext

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/... von Loriot, Yohann, Fizazi, Karim, Jones, Robert J., Van den Brande, Jan, Molife, Rhoda L., Omlin, Aurelius, James, Nicholas D., Baskin-Bey, Edwina, Heeringa, Marten, Baron, Benoit, Holtkamp, Gertjan M., Ouatas, Taoufik, De Bono, Johann S.

Volltext

FGF Receptor Inhibitors: Role in Cancer Therapy von Daniele, Gennaro, Corral, Jesus, Molife, L. Rhoda, de Bono, Johann S.

Volltext

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors von Sarker, Debashis, Molife, Rhoda, Evans, T R Jeffrey, Hardie, Maryon, Marriott, Cheryl, Butzberger-Zimmerli, Priska, Morrison, Rosemary, Fox, Judith A, Heise, Carla, Louie, Sharianne, Aziz, Natasha, Garzon, Felix, Michelson, Glenn, Judson, Ian R, Jadayel, Dalal, Braendle, Edgar, de Bono, Johann S

Volltext

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy von Perez-Lopez, Raquel, Roda, Desam, Jimenez, Begona, Brown, Jessica, Mateo, Joaquin, Carreira, Suzanne, Lopez, Juanita, Banerji, Udai, Molife, L Rhoda, Koh, Dow-Mu, Kaye, Stan B, de Bono, Johann S, Tunariu, Nina, Yap, Timothy A

Volltext

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor von Barber, Louise J, Sandhu, Shahneen, Chen, Lina, Campbell, James, Kozarewa, Iwanka, Fenwick, Kerry, Assiotis, Ioannis, Rodrigues, Daniel Nava, Reis-Filho, Jorge S, Moreno, Victor, Mateo, Joaquin, Molife, L Rhoda, De Bono, Johann, Kaye, Stan, Lord, Christopher J, Ashworth, Alan

Volltext

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors von Molife, L. Rhoda, Rudman, Sarah M., Alam, Salma, Tan, Daniel S.-W., Kristeleit, Hartmut, Middleton, Gary, Propper, David, Bent, Liz, Stopfer, Peter, Uttenreuther-Fischer, Martina, Wallenstein, Gudrun, de Bono, Johann, Spicer, James

Volltext